Old drug, new hope: lenalidomide tackles rare histiocyte cancers
NCT ID NCT02523040
First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 2 times
Summary
This phase 2 study tests the chemotherapy drug lenalidomide (Revlimid) in 12 adults with one of three rare histiocyte disorders: Langerhans cell histiocytosis, Erdheim-Chester disease, or histiocytic sarcoma. The goal is to see how many patients achieve disease control or remission. The trial is no longer recruiting but is still analyzing results.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- lenalidomide (Revlimid)
- What this could lead to
- If it works, this could point toward a new treatment option for rare histiocyte disorders that are hard to treat.
- What could go wrong
- This is a very small, early-phase trial with only 12 participants, so results may not apply broadly. Lenalidomide is a chemotherapy drug and can cause side effects like low blood counts and fatigue.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HISTIOCYTIC SARCOMA (HS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could existing cancer drugs tackle rare tumors? new trial aims to find out
- New targeted drug combo aims to curb relapse in kids with rare immune disorder
- Scientists hunt for genetic clues in rare blood disorders
- New pill could spare kids with rare bone disease from chemo
- New pill shows promise for rare childhood diseases
- New hope for rare cancer: drug cocktail targets stubborn LCH